Since 2019, the World Health Organization (WHO) has included the regulation of blood and blood products in its global assessment system for medicine authorities, the Global Benchmarking Tool (GBT). Until now, no official WHO benchmarking using the extended GBT + Blood tool has been performed. However, the self-assessment using this…
Context The availability, safety and quality of blood and blood products is an essential component of any health care system. The WHO has therefore listed them as essential medicines. Blood products are life-saving for many patients, in particular for women with pregnancy-related complications, children suffering from severe anaemia and people…
Short Description Blood and blood products are important medical products, acknowledged as indispensable by the World Health Organization (WHO). However, in many African countries, there is a deficiency in both the quantity and quality of available blood reserves. The procedures for performing, processing, storing, and testing blood donations are often…
Short Description Ensuring the availability, quality and integrity of medicinal products worldwide remains critical and challenging for healthcare systems today. Patient safety is at the core of high-quality healthcare. Sub-standard drugs/poor quality products have a negative impact on the safety and effectiveness of treatments as well as directly contributing to…
Short Description The current COVID-19 pandemic highlighted the importance of efficient and robust drug regulatory authorities to ensure healthy lives and well-being for all. Well-functioning regulatory systems ensure the quality, safety and efficacy of medicines and contribute to timely access to essential medical products. Resilient regulatory systems with well-functioning structures,…
Short Description CPA facilitates collaborative research on optimal use of anti-infective drugs as a means to combat antimicrobial resistance. The research projects under CPA will help fill important gaps in knowledge about locally-relevant, real-world hospital practice and ways in which scientific training on appropriate drug use may assist healthcare professionals…
GHPP CPA supports efforts of African researchers and clinicians in the prudent use of antimicrobial drugs in low- and middle- income countries (LMICs). These countries have the highest rates of antimicrobial resistance (AMR) driven by high rates of antimicrobial utilisation. Pharmacogenomics (PGx) and Precision Medicine are emerging approaches to combat…
At the end of the first phase of the GHPP-DQA project, alumni and trainers from all DQA trainings as well as project staff from BfArM, InphA and WHO met for a virtual alumni meeting. The central point was a review of the activities and achievements of the DQA project so…
Inspections contribute to blood safety and effectiveness Blood establishments do not only collect blood from donors, they often also have the license to further process the blood into the components needed for therapy. For this processes and manufacturing, blood establishments must comply with requirements – for example, for donor selection…